Kiadis Pharma’s primary objective is to become a leading biopharmaceutical company focused on developing and commercializing therapeutic products in cell-based immunotherapy.

Manfred Rüdiger PhD
Chief Executive Officer

Kiadis Pharma

Life-saving therapies for blood cancer patients and patients with inherited blood disorders

Kiadis Pharma’s primary objective is to become a leading biopharmaceutical company focused on developing and commercializing therapeutic products in cell-based immunotherapy.
We aim to develop products that provide safer and more efficacious treatment options for blood cancer and blood disorder patients, improving their survival rate and quality of life.

We are focused on two therapeutic indications: leukemia (a common form of blood cancer) and thalassemia (an inherited blood disorder).

Our lead product candidate is ATIR101 in blood cancers and is being developed to make HSCT a safer and more effective procedure.

ATIR101 in blood cancers works by administering additional immune cells to a patient after HSCT, enabling that patient to better fight infections and eliminate residual tumor cells. This procedure has the potential to reduce the number of patient deaths caused by opportunistic infections and cancer relapse following a transplantation of stem cells from a donor. Risks such as the occurrence of potentially lethal Graft-versus-Host-Disease (GVHD) are currently limiting the application of HSCT to patients who are at high risk of relapse, who do not respond fully to treatment, or who relapse after prior successful treatment.

In December 2016, the Company reported positive results from its single dose Phase II clinical trial with ATIR101. The study was designed as an open-label trial in patients with blood cancer who had not found a matching donor and where a partially matched (haploidentical) family member was used as donor for HSCT. The data showed that one year post transplantation, ATIR101 significantly reduced Transplant Related Mortality (TRM) and significantly improved Overall Survival (OS) in comparison to a historical control group of patients undergoing a T-cell depleted haploidentical donor transplantation only. In addition, ATIR101 did not elicit grade III-IV GVHD in any patient.

Based on these results, Kiadis Pharma ihas initiated a randomized Phase III clinical trial with ATIR101 as an adjunctive immunotherapeutic treatment to a haploidentical HSCT for patients with acute leukemia.

In addition, the Company is now enrolling blood cancer patients in a further Phase II trial to study the safety and efficacy of administrating a second dose of ATIR101 to further improve the HSCT outcome.

Our second product candidate is ATIR201 for thalassemia and we have recently initiated Pase I/II clinical development for ATIR201 in patients with beta-thalassemia major.

Our product candidates are derived from the Theralux product platform, which is based on the TH9402 compound which selectively targets and eliminates rapidly dividing cells such as cancer cells and immune reactive cells, including T-cells that can cause GVHD.

Kiadis Pharma is headquartered in Amsterdam, The Netherlands, and works closely with renowned centers in Europe and North America.